EP2951277A1 - Vorrichtung zur extraktion von trocken vorgelagerter körperflüssigkeit in einer probe, kartusche sowie verfahren - Google Patents
Vorrichtung zur extraktion von trocken vorgelagerter körperflüssigkeit in einer probe, kartusche sowie verfahrenInfo
- Publication number
- EP2951277A1 EP2951277A1 EP13814576.8A EP13814576A EP2951277A1 EP 2951277 A1 EP2951277 A1 EP 2951277A1 EP 13814576 A EP13814576 A EP 13814576A EP 2951277 A1 EP2951277 A1 EP 2951277A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sample
- body fluid
- extraction
- dry
- upstream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001124 body fluid Anatomy 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title claims description 22
- 239000012876 carrier material Substances 0.000 claims abstract description 35
- 239000010839 body fluid Substances 0.000 claims description 74
- 238000000605 extraction Methods 0.000 claims description 57
- 238000011144 upstream manufacturing Methods 0.000 claims description 32
- 238000010828 elution Methods 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 238000002604 ultrasonography Methods 0.000 claims description 8
- 230000006862 enzymatic digestion Effects 0.000 claims description 7
- 238000005086 pumping Methods 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims 1
- 238000002032 lab-on-a-chip Methods 0.000 abstract description 3
- 238000007599 discharging Methods 0.000 abstract 2
- 239000000523 sample Substances 0.000 description 77
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 18
- 239000008188 pellet Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 10
- 230000008901 benefit Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000002791 soaking Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000003851 biochemical process Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 229960002378 oftasceine Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- -1 polytetrafluoroethylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920005721 BUTONAL® Polymers 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 239000004734 Polyphenylene sulfide Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000069 polyphenylene sulfide Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502707—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the manufacture of the container or its components
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0832—Geometry, shape and general structure cylindrical, tube shaped
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/087—Multiple sequential chambers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0409—Moving fluids with specific forces or mechanical means specific forces centrifugal forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0433—Moving fluids with specific forces or mechanical means specific forces vibrational forces
- B01L2400/0439—Moving fluids with specific forces or mechanical means specific forces vibrational forces ultrasonic vibrations, vibrating piezo elements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0633—Valves, specific forms thereof with moving parts
- B01L2400/0644—Valves, specific forms thereof with moving parts rotary valves
Definitions
- Liquids Liquids. Typically, this manipulation is done manually with tools such as pipettes, reaction vessels, active probe surfaces or laboratory equipment. By tilting robots or special equipment, these processes are already partially automated.
- Lab-on-a-Chip systems are microfluidic systems that accommodate the entire functionality of a macroscopic laboratory on a plastic card-sized plastic substrate.
- Lab-on-a-chip systems typically consist of two
- a test carrier or disposable cartridge includes structures and mechanisms for the implementation of basic fluidic operations (e.g., mixers), which may consist of passive components such as channels, reaction chamber, upstream reagents, or even active components such as valves or pumps.
- the second main component is actuation, detection and control units.
- One of the primary means used to diagnose a person's condition is the analysis of the person's blood or other bodily fluids for the presence or absence of "analytes" indicative of the person's health.
- Certain body fluids, such as urine, saliva, semen, and the like a. can be obtained noninvasively, and the analysis of such fluids can
- Body fluid which, however, usually provides the most complete picture of a person's health, is the whole blood.
- the process is cumbersome and expensive because it requires the blood or other sample to be collected either in a location that has all the equipment required, or that the sample is cooled and shipped to a separate laboratory for further processing. It also takes a considerable amount of time to obtain the analysis results. However, time can be critical to the life or health of the patient.
- DBS Dried Blood Spots
- DBS digital filter spherical blood
- a few drops of capillary blood are applied to simple filter paper.
- the use of DBS has several advantages over the classical whole blood / plasma sample, which is currently still the most common type of sample.
- One of the greatest advantages is the possibility of storing the DBS at room temperature, which simplifies the transport from the patient to the analytical laboratory and makes it more cost-effective.
- Another advantage is the small sample volume required of 10 to 30 ⁇ blood for DBS compared to 100 to 500 ⁇ for the plasma samples. This advantage is particularly important when children or small animals, such as rodents, should be sampled.
- Dry blood in a form acceptable to the diagnosis (usually liquid) from filter material can be expensive. It may also be difficult to separate the dissolved aqueous sample from the solid filter material. Once the analyte is dissolved, sometimes another purification step is needed. All of these steps require many disposable parts (e.g., pipette tips, MTP, plastic containers) and process steps that often involve multiple different devices.
- Cartridge and the method defined in claim 1 1 have the advantage over conventional solutions that it is now possible to dry To extract upstream samples (such as DBS samples) for any dry bodily fluids in a microfluidic system by means of a LoC system in a simple manner and optionally further below
- Body fluids in a sample smaller sample volumes sufficient for an analysis, so that the method is especially suitable for infants or small animals or even with repeated removal of samples for the patient is gentler. Therefore, with the present device, advantageously dry bodily fluids in a sample can be examined, which are obtained in a less invasive and patient-friendly manner.
- the present device is particularly advantageous for the extraction of dry bodily fluids of all kinds from a sample such as urine, sputum, lavage, saliva, ejaculate / sperm, pericardial fluid, pleural fluid, abdominal fluid, peritoneal dialysate (CAPD), drainage fluid,
- a sample such as urine, sputum, lavage, saliva, ejaculate / sperm, pericardial fluid, pleural fluid, abdominal fluid, peritoneal dialysate (CAPD), drainage fluid,
- Bronchoalveolar lavage BALF
- cerebrospinal fluid gastric juice
- sweat lymph
- bile pancreatic secretions
- blood breast milk
- vaginal secretions of the woman tears, nasal secretions, brain water, ascites, pleural fluid, amniotic fluid, earwax, pus, synovium, menstrual fluid, aqueous humor of the eye, etc ,
- Possible applications for the device according to the invention for the extraction of dry body fluid in a sample include, for example:
- Infection diagnostics and therapy support and screening for example HIV, HPV, STD, hepatitis etc.
- the extraction of the dry body fluid upstream of the sample by incubation in an elution solution realizes soaking of the carrier material together with the dry body fluid of the sample until the analytes have dissolved from the carrier material. It can do that
- Soaking can also be done at elevated temperatures.
- various water-based or organic solutions come into question.
- alcohols especially ethanol, butonal, isopropanol, methanol, etc
- Buffer solutions with water for example PBS, Tween, HEPES and sodium azide
- organic substances for example organic acids or bases etc.
- protein-containing solutions for example milk, BSA, calcein
- inorganic solutions for example acids and bases
- the extraction of the dry body fluid upstream of the sample by means of a pumping function of an elution solution through the sample over a predetermined time takes place.
- the extraction can be effected by means of a pumping function by the elution solution for the predetermined time by the sample, in particular the carrier material of the sample, reciprocated back and forth.
- the extraction of the dry body fluid upstream of the sample takes place by means of ultrasound.
- ultrasound should be used with a frequency which both leads to the extraction of body fluid from the carrier material and excludes damage or alteration of the body fluid during the extraction.
- frequencies in a range of 20 kHz to 50 MHz should be used.
- the power density should preferably be less than 1 W / cm 2 .
- the extraction of the dry body fluid upstream of the sample by means of enzymatic digestion of the carrier material by enzymes.
- the extraction of the dry-upstream body fluid from the carrier material can be accomplished by a specific enzymatic digestion of the carrier material by enzymes.
- enzymes may be proteases, proteinases or
- proteolytic enzymes such as those used for the cleavage of, for example, proteins or peptides, in biological or bio-chemical processes.
- the sample is placed horizontally, vertically or inclined relative to the device on the receiving area.
- the device according to the invention may require a differently oriented recording of the sample on the device.
- the device may require a differently oriented recording of the sample on the device.
- the receiving area to be pivotally formed relative to the Lab On Chip system has a carrier which is pivotally coupled to the Lab On Chip system and is used for receiving the sample.
- the device according to the invention is the
- a filter or a purification device for the body fluid extracted from the sample is provided.
- the purification device for example in the delivery area of the lab-on-chip system, in operative connection with a microfluidic channel, which connects the receiving area to the delivery area, a DNA purification, a protein purification, an ion exchanger, an antibody-based purification of blood components, etc . be provided.
- the carrier material of the sample is made of a degradable or dissolvable material, of a filter material or consists of a polymer.
- a degradable material preferably an enzymatic-digestible material is provided, such as cellulose.
- a dissolvable material preferably a liquid-soluble material is provided, such as gelatin.
- filter materials it is possible to use surface filters or fabric filters which comprise, for example, PVDF, silica matrix, felts, spunbonded nonwovens, paper, woven fabrics, synthetic fibers
- the carrier material of the sample consists of glass as fibers or of glass beads.
- Glass beads may each be provided with a smooth, rough or textured surface, including blends of differently shaped ones
- the different carrier materials can also be processed chemically and / or physically so as to be able to provide a desired property.
- a cartridge comprising a device according to the invention for the extraction of dry body fluid upstream in a sample, a housing of the cartridge, a drum having at least one chamber, wherein the device is disposed inside the drum.
- Preventive body fluids in a sample is no longer necessary, since all process steps now take place in the LoC system, which is much cheaper to purchase. Furthermore, further steps for the preparation of the extracted body fluid from the sample can be realized in the cartridge, so that the processed body fluid can be provided for a subsequent analysis.
- a method for extracting a dry body fluid from a sample comprising the steps of:
- the extraction of the dry body fluid upstream of the sample is carried out by incubation in a Elutionslosung. This extraction process realizes soaking of the carrier material together with the dry body fluid of the sample until the analytes have dissolved from the carrier material. It can do that
- Soaking can also be done at elevated temperatures.
- the above-described water-based or organic solutions come into question.
- the extraction of the dry body fluid upstream of the sample by means of a pumping function of a Elutionslosung carried out by the sample over a predetermined time can be carried out by means of a pumping function by the elution solution for the predetermined time by the sample, in particular the support material of the sample, pumped back and forth.
- Extraction process is possible with control of temperature and / or pressure during extraction.
- the extraction of the dry body fluid upstream of the sample takes place by means of ultrasound.
- ultrasound should be used with a frequency which both leads to the extraction of body fluid from the carrier material and excludes damage or alteration of the body fluid during the extraction.
- the extraction of the dry body fluid upstream of the carrier material can be carried out by a specific, enzymatic digestion of the carrier material by enzymes.
- FIG. 1 shows a schematic perspective view of a device according to the invention for the extraction of dry body fluid in a sample
- FIG. 2 shows a schematic perspective view of the device according to FIG. 1, wherein the sample is placed in a receiving area of the device, FIG.
- Figs. 3A to 3C is a schematic view of extraction methods for extracting dry body fluid from a sample according to the present invention
- FIG. 4 shows a schematic view of a further extraction process for a dry body fluid in a sample according to the present invention
- FIG. 5 shows a schematic view of a region of the device according to the invention, which is used for the purification of an extracted body fluid from the sample
- FIG. 6 shows a cartridge with a device according to the invention for the extraction of dry body fluid in a sample according to the present invention.
- FIG. 1 shows, in a simplified and schematic illustration, a device 100 according to the invention for extracting dry body fluid (not shown) in a sample 30.
- the device 100 has a lab-on-chip system 10 with a receiving region 20, which holds the sample 30 with the
- Body fluid in dry pre-stored form in a carrier material is provided. Furthermore, the lab-on-chip system 10 has a delivery region 50 for delivering the extracted body fluid from the sample 30, which is operatively connected to the acquisition region 20 via a microfluidic channel (not shown). The extraction of the dry body fluid from the sample 30 takes place in the receiving area 20.
- the use of a DBS pellet for sample 30 is described below by way of example. However, for use in the present apparatus 100, any types of samples containing dry body fluid may be used.
- the pellet 30 is inserted into the LoC system 10, namely into the receiving area 20.
- the pellet 30 can be inserted into the receiving area 20 either horizontally, obliquely or vertically.
- FIG. 2 shows a schematic perspective view of the device 100 according to FIG. 1, wherein the pellet 30 is placed in the receiving region 20 of the device 100. After placing the pellet 30 in the receiving area 20, the blood sample is extracted. The extraction can take place in different ways. Subsequently, the extracted blood sample is delivered to the delivery area 50 of the device 100 to the environment (not shown), preferably by means of a hose (not shown).
- Figs. 3A to 3C show a schematic view of extraction methods for extraction of dry body fluid from a sample according to the present invention.
- FIG. 3A shows a first method according to the invention for extracting a dry body fluid (not shown) from a sample 30
- Sample 30 is separated from the carrier material 40 of the sample 30 by incubation in an elution solution.
- This extraction process realizes soaking of the carrier material 40 together with the dry body fluid of the sample 30 until the analytes have dissolved from the carrier material 40.
- the soaking can be done even at elevated temperatures.
- various water-based or organic solutions come into question.
- alcohols in particular ethanol, butanol, isopropanol, methanol, etc.
- buffer solutions with water for example PBS, Tween, HEPES and sodium azide
- organic substances for example organic acids or bases etc.
- protein-containing solutions for Example, milk, BSA, calcein
- inorganic solutions for example acids and bases
- Fig. 3B shows a second method according to the invention for extracting a dry body fluid (not shown) by means of a pumping function.
- an elution solution 60 is pumped back and forth for a predetermined time by a sample 30, in particular the carrier material 40 of the sample 30.
- An optimization of Efficiency of the extraction method of the invention is possible with control of temperature and / or pressure during extraction.
- 3C shows a third method according to the invention for extracting a dry body fluid (not shown) from a sample 30 by means of ultrasound.
- ultrasound should be used with a frequency which both leads to the extraction of body fluid from the carrier material 40 of the sample 30 and excludes damage or change of body fluid during the extraction. It is preferable to use frequencies in a range of 20 kHz to 50 MHz.
- the power density should preferably be less than 1 W / cm 2 .
- FIG. 4 shows a schematic view of a fourth extraction process for a dry body fluid (not shown) in a sample 30 according to the present invention.
- a blood sample in the form of a pellet 30 is stored on an enzymatically digestible cellulosic carrier material 40.
- the extraction of the blood sample from the carrier material 40 takes place by specific, enzymatic digestion of the carrier material 40 by enzymes 70.
- enzymes 70 As an example of such enzymes proteases, proteinases or proteolytic enzymes may be mentioned, as they are used for the cleavage of, for example, proteins or peptides, in biological or bio-chemical processes.
- Fig. 5 shows a schematic view of a portion of the invention
- a filter function 80 is arranged downstream in a microfluidic channel 90.
- a purification function (not shown), such as DNA purification, protein purification, ion exchange, antibody-based purification of blood components, etc., may also be provided in the microfluidic channel 90.
- FIG. 6 shows a cartridge 200 with a device according to the invention (not shown) for extracting dry body fluid (not shown) in a sample 30.
- the cartridge 200 comprises a housing 210, which has a housing
- the cartridge 200 has in its interior three drums 220, 221, 222, which along the axis of rotation 235 of the cartridge 200 on top of each other and are arranged congruent to each other.
- Each drum 220, 221, 222 in turn has at least two chambers 230, 231 in its interior, which are provided for receiving different reagents and for one or more analytes (here the DBS pellet 30).
- the individual drums 220, 221, 222 are rotated along the rotational axis 235 of the cartridge 200 by the action of centrifugal force by means of a so-called "ballpoint pen mechanism" (not shown).
- FIG. 6 shows a possible embodiment for a drum 220 in which the DBS pellet 30 or other dry-stored body fluid is introduced into the drum 220 from above.
- the right side of FIG. 6 shows another embodiment of a drum 220 in which the DBS pellet 30 is inserted laterally through an opening 240 in the drum 220.
- the proposed device according to the invention for the extraction of dry bodily fluid in the LoC system can be located in a chamber 230 of one of the drums 220, 221, 222.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102013201505.4A DE102013201505A1 (de) | 2013-01-30 | 2013-01-30 | Vorrichtung zur Extraktion von trocken vorgelagerter Körperflüssigkeit in einer Probe, Kartusche sowie Verfahren |
PCT/EP2013/078086 WO2014117908A1 (de) | 2013-01-30 | 2013-12-27 | Vorrichtung zur extraktion von trocken vorgelagerter körperflüssigkeit in einer probe, kartusche sowie verfahren |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2951277A1 true EP2951277A1 (de) | 2015-12-09 |
EP2951277B1 EP2951277B1 (de) | 2021-04-14 |
Family
ID=49885280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13814576.8A Active EP2951277B1 (de) | 2013-01-30 | 2013-12-27 | Verfahren zur extraktion von trocken vorgelagerter körperflüssigkeit in einer probe |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2951277B1 (de) |
DE (1) | DE102013201505A1 (de) |
WO (1) | WO2014117908A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3478412T3 (pl) * | 2016-06-30 | 2020-10-19 | Sarstedt Ag & Co. Kg | Urządzenie do dostarczania chłonnych nośników próbek zawierających wysuszoną ilość cieczy, a w szczególności krew |
DE102018200520A1 (de) * | 2018-01-15 | 2019-07-18 | Robert Bosch Gmbh | Verfahren zum Bereitstellen einer Lösung der Substanz in einer mikrofluidischen Vorrichtung |
CN108393105B (zh) * | 2018-04-20 | 2023-08-25 | 华南师范大学 | 一种微流控芯片及其控制***、控制方法 |
DE102022206246A1 (de) | 2022-06-22 | 2023-12-28 | Robert Bosch Gesellschaft mit beschränkter Haftung | Mikrofluidiksystem mit Ionenaustauscher-Mischbettharz |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008042581B4 (de) * | 2008-10-02 | 2012-02-02 | INSTITUT FüR MIKROTECHNIK MAINZ GMBH | Mikrofluidische Extraktions- und Reaktionsvorrichtung |
CA2798123C (en) * | 2010-05-05 | 2020-06-23 | The Governing Council Of The University Of Toronto | Method of processing dried samples using digital microfluidic device |
US10016757B2 (en) * | 2011-04-28 | 2018-07-10 | Labcyte Inc. | Sample containers adapted for acoustic ejections and sample preservation and methods thereof |
DE102011077134A1 (de) * | 2011-06-07 | 2012-12-13 | Robert Bosch Gmbh | Kartusche, Zentrifuge sowie Verfahren zum Mischen einer ersten und zweiten Komponente |
-
2013
- 2013-01-30 DE DE102013201505.4A patent/DE102013201505A1/de not_active Withdrawn
- 2013-12-27 EP EP13814576.8A patent/EP2951277B1/de active Active
- 2013-12-27 WO PCT/EP2013/078086 patent/WO2014117908A1/de active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2014117908A1 (de) | 2014-08-07 |
EP2951277B1 (de) | 2021-04-14 |
DE102013201505A1 (de) | 2014-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE102006002258B4 (de) | Modul zur Aufbereitung einer biologischen Probe, Biochip-Satz und Verwendung des Moduls | |
EP3663387B1 (de) | Vorrichtung und verfahren zum aufbereiten von flüssigkeiten, insbesondere körperflüssigkeiten | |
DE202008011578U1 (de) | Flüssigkeitstransfervorrichtung | |
EP2951277B1 (de) | Verfahren zur extraktion von trocken vorgelagerter körperflüssigkeit in einer probe | |
EP2087934A1 (de) | Verfahren und Vorrichtung zur automatisierten Prozessierung einer Probe | |
WO2009144173A2 (de) | Titerplatte, leseeinrichtung hierfür und verfahren zur detektion eines analyten, sowie deren verwendung | |
DE212013000295U1 (de) | Vorrichtungen zum Einfangen von Zielmolekülen | |
EP2477743A1 (de) | Einweg-vorrichtung zur aufbewahrung von biologischen flüssigkeiten und deren verwendung zum nachweis von stoffen, partikel und/oder zellen | |
WO2015018647A1 (de) | Verfahren und vorrichtung zum aufbereiten einer zielzellen und begleitzellen enthaltenden probe biologischen materials zum extrahieren von nukleinsäuren der zielzellen | |
EP2937144B1 (de) | Verfahren und mikrofluidisches system zum aufbereiten von organischen zellen und herstellungsverfahren zum herstellen eines mikrofluidischen systems zum aufbereiten von organischen zellen | |
EP1740296B1 (de) | Verfahren zur herstellung einer lösung, zugehörige anordnung sowie anwendungen des verfahrens und der anordnung | |
DE102014205728B3 (de) | Chiplabor-Kartusche für ein mikrofluidisches System zum Analysieren einer Probe biologischen Materials, mikrofluidisches System zum Analysieren einer Probe biologischen Materials sowie Verfahren und Vorrichtung zum Analysieren einer Probe biologischen Materials | |
EP3684515B1 (de) | Inkubationsvorrichtung sowie system mit inkubationsvorrichtung und wipptisch | |
EP3784140A1 (de) | Vorrichtung und verfahren zum vorbereiten von probenmaterial | |
EP3973288A1 (de) | Mikrofluidisches analysesystem zur analyse von blutproben | |
EP2893980A1 (de) | Mikrofluidisches System sowie Verfahren zum Analysieren einer Probe biologischen Materials | |
WO2012095200A1 (de) | Reagenzienkartusche, prozessier-chip, analyse-kit damit und analyseverfahren | |
DE202007014762U1 (de) | Anordnung zur Aufbereitung von zu untersuchendem Gewebe sowie Objektträger für zu untersuchendes Gewebe | |
DE102021212645A1 (de) | Vorrichtung und Verfahren zur Durchführung mikrofluidischer Prozessschritte | |
WO2023110319A1 (de) | Vorrichtung und verfahren zum splitten dreidimensionaler agglomerate | |
DE102021214276A1 (de) | Vorrichtung und Verfahren zum Splitten dreidimensionaler Agglomerate | |
DE102021203634A1 (de) | Mikrofluidische Vorrichtung und Verfahren zum Betreiben einer mikrofluidischen Vorrichtung | |
WO2020161013A1 (de) | Mikrofluidikeinrichtung und verfahren zum abtrennen von blutserum | |
DE202018006869U1 (de) | Mikrofluidisches System für die digitale Polymerasekettenreaktion (dPCR) einer biologischen Probe | |
DE102017220531A1 (de) | Adapter für eine mikrofluidische Vorrichtung zur Überführung einer Substanz, insbesondere einer Probe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150831 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20161116 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ROBERT BOSCH GMBH |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20201223 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 502013015653 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1382400 Country of ref document: AT Kind code of ref document: T Effective date: 20210515 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20210414 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210816 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210715 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210814 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 502013015653 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20220117 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210814 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20211227 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20211231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211227 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211227 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 1382400 Country of ref document: AT Kind code of ref document: T Effective date: 20211227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20131227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210414 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240227 Year of fee payment: 11 |